T-cell receptor specific for tumor-derived peptide–MHC complex (TCR-pMHC)

T-cell receptors (TCRs) specific for tumor-derived peptide–MHC (pMHC) complexes are specialized heterodimeric surface proteins that mediate the recognition of intracellular antigens by the adaptive immune system. Unlike Chimeric Antigen Receptors (CARs), which are restricted to recognizing surface-expressed proteins, TCRs can identify a vast repertoire of internal tumor-associated antigens (TAAs) or neoantigens that are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules (NIH, 2023). This capability makes them highly valuable for targeting solid tumors where surface antigens may be scarce or non-specific. In therapeutic applications, such as TCR-engineered T-cell (TCR-T) therapy or soluble bispecific T-cell engagers (ImmTACs), these receptors are optimized to bind specific pMHC targets with high affinity and selectivity (Nature Reviews Clinical Oncology, 2022). Upon binding, the TCR complex initiates a signaling cascade through the CD3 subunits, leading to T-cell activation and the targeted destruction of malignant cells. However, the clinical use of these receptors requires precise HLA matching and rigorous screening to prevent lethal cross-reactivity with similar peptides in healthy tissues, as seen in early trials targeting MAGE family proteins (Journal of Hematology & Oncology, 2022).

Other names

Tumor-specific T-cell receptorAntigen-specific T-cell receptorTCR-pMHC complexEngineered T-cell receptorTumor-infiltrating lymphocyte receptor

Engineered or naturally occurring T-cell receptors (TCRs) recognize specific intracellular tumor antigens that have been processed into peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules. Upon high-affinity binding to the pMHC complex, the TCR initiates a signaling cascade through the associated CD3 complex, leading to T-cell activation, proliferation, and the release of cytotoxic granules such as perforin and granzymes to induce apoptosis in the target tumor cell (Nature Reviews Drug Discovery, 2021).